SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHeSYS study

SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHeSYS study

Bibliographic Details
Main Authors: François D’heygere, Christophe George, François Habersetzer, Davender Tripathi, Calvin Q. Pan, Jose A. Giron, Manuela Schmitz, Fernando Tatsch
Format: Article
Language:English
Published: Elsevier 2014-03-01
Series:Annals of Hepatology
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119308968

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119308968

Similar Items